Economic impact of multiple sclerosis disease-modifying drugs in an employed population: Direct and indirect costs

Current Medical Research and Opinion

Volumn 25, Issue 4, 2009, Pages 869-877

  Birnbaum, Howard G ^a   Ivanova, Jasmina I ^a   Samuels, Seth ^a   Davis, Matthew ^a   Cremieux, Pierre Y ^a   Phillips, Amy L ^b   Meletiche, Dennis ^b  

^a ANALYSIS GROUP   (United States)

^b EMD SERONO INC   (United States)

Author keywords

Direct and indirect costs; Disease modifying drugs; Multiple sclerosis; Work loss

Indexed keywords

ANTICONVULSIVE AGENT; BETA1A INTERFERON; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MUSCLE RELAXANT AGENT; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; PREDNISONE; SALICYLIC ACID DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VASOPRESSIN;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST CONTROL; COST OF ILLNESS; DATA BASE; DRUG USE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDY; WORK DISABILITY;

ADOLESCENT; ADULT; COMORBIDITY; COST OF ILLNESS; DISABLED PERSONS; DRUG THERAPY; EMPLOYMENT; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; UNITED STATES; YOUNG ADULT;

EID: 67649312050     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902743869     Document Type: Article

References (18)

1. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend in women. Neurology 2002;59:136-138 (Pubitemid 34041953)
2. Roessler R, Fitzgerald S, Rumrill P, et al. Multiple sclerosis and employment barriers: A systematic perspective on diagnosis and intervention. Work 2003;21:17-23 (Pubitemid 37038328)
3. Birnbaum HG, Ivanova JI, Samuels S, et al. The cost of disability and medically-related absenteeism among employees with multiple sclerosis. Value Health 2008;11:A143
4. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002;58:37-43 (Pubitemid 34041935)
5. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-476
6. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
7. Bourdette DN, Prochazka AV, Mitchell W, et al. VA Multiple Sclerosis Rehabilitation Study Group. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. Arch Phys Med Rehabil 1993;74:26-31
8. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425 (Pubitemid 28515352)
9. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276
10. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000;6:255-266 (Pubitemid 30675990)
11. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294 (Pubitemid 26100751)
12. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-363 (Pubitemid 27368867)
13. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007;29:2031-2048 (Pubitemid 350218119)
14. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910 (Pubitemid 43313657)
15. Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Neurology 2008;71:766-773
16. Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work 2006;27:143-151 (Pubitemid 44355728)
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
18. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1075-1079